Publications by authors named "D Vassilief"

Claim this Profile
D
Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies).
Christian Rose, Sabine Brechignac, Dominique Vassilief, Laurent Pascal, Aspasia Stamatoullas

Leuk Res· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
J Tamburini, C Elie, S Park, O Beyne-Rauzy, M Gardembas, D Vassilief

Leuk Res· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a role for all-trans retinoic acid in combination with recombinant erythropoetin in myelodysplastic syndromes? A report on 59 cases.
R Itzykson, S Ayari, D Vassilief, E Berger, B Slama

Leukemia· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des Myélodysplasies.
Didier Bouscary, Laurence Legros, Micheline Tulliez, Stéphanie Dubois, Béatrice Mahe, Dominique Vassilief

Br J Haematol· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications.
D Magli-Barioz, N Ounnoughène, P Paugy, M-C Quarrè, D Vassilief

Haemophilia· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis